An innovative ventilation solution for cardiac arrest
Every year, 50,000 people die prematurely from a cardiac arrest in France. The survival rate without after-effects to a cardiac arrest does not exceed 5%. To prevent this phenomenon, Air Liquide, in partnership with the Annecy Genevois Hospital in France, has developed the first ventilator dedicated to cardiopulmonary resuscitation, specifically designed to act as an intelligent assistant to first-aid workers, accident and emergency doctors and clinicians when treating victims of cardiac arrest. The CPV (Cardio Pulmonary Ventilation) system was designed following the immersion of Air Liquide people in the emergency services to meet the specific needs of these teams.
To optimize ventilation, which is essential during cardiopulmonary resuscitation, the CPV innovation combines, for the first time in one ventilator, continuous thoracic compression, effective ventilation and dedicated monitoring (display of information such as the quality of compressions and the fraction of CO2 expired). Therefore, the entire system contributes to improving the quality of patient care.
Unlike the manual insufflator, CPV is an entirely automated method that frees up the practitioner’s hands. The latter can then concentrate on coordinating the team, managing the patient and his/her family. The clinical indicators of the person being treated, visible in real time on the ventilator screen, are used to guide the teams: CPV shows whether faster or softer compression is needed and encourages the cardiac massage to be interrupted as little as possible. Oxygenation and ventilation are improved and the effectiveness of the cardiac massage is optimized. In France, more than one hundred cardiac arrest patients have already benefited from treatment including this specific and innovative ventilation method. Air Liquide is also targeting export markets and is continuing its approach of co-innovation with international research centers, in Canada in particular.